Survival time in a population-based consecutive series of adult acute myeloid leukemia – the prognostic impact of karyotype during the time period 1976–1993

Mauritzson, Nils; Johansson, Bertil; Albin, María; Rylander, Lars; Billström, Rolf; Ahlgren, Tomas; Mikoczy, Zoli; Strömberg, Ulf; Mitelman, Felix; Hagmar, Lars; Nilsson, Per‐Gunnar

doi:10.1038/sj.leu.2401788

Cited by 15 publications

(13 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[13][14][15] In fact, the prognostic value of these two chromosome aberration groups was not significantly different among AML patients, 15 but sufficient data for MDS were lacking. The present study demonstrates that the prognosis of patients who carry À5 and del(5q) are significantly different, as OS and LFS of À5 group were shorter than del(5q) patients even if 5q-syndrome patients were excluded from del(5q) patients ( Figure 2 and data not shown).…”

Section: Discussionmentioning

confidence: 99%

Myelodysplastic syndrome with chromosome 5 abnormalities: a nationwide survey in Japan

et al. 2008

View full text Add to dashboard Cite

Chromosome 5 abnormalities, deletion of the long arm of chromosome 5 (del(5q)) or monosomy 5 (À5), arise in about 10% of myelodysplastic syndromes (MDS), either as the sole cytogenetic abnormality or as part of complicated karyotype, and has distinct clinical implications for MDS. However, the prognostic factors of MDS patients with chromosome 5 abnormalities are not determined yet. In this study, 183 Japanese MDS patients with chromosome 5 abnormalities were analyzed. Estimated incidence of del(5q) and 5q-syndrome among MDS patients was 8.4 and 1.3%, respectively. Significant shorter overall survival (OS) and leukemia-free survival (LFS) were observed in À5 patients than del(5q) patients. Among del(5q) patients, addition of monosomy 7 or complex karyotype with more than three abnormalities were significantly related to shorter OS.LFS of del(5q) patients was divided into two risk groups by international prognostic scoring system (IPSS): low/intermediate (Int)-1 and Int-2/high groups. LFS sorted by World Health Organization classification-based prognostic scoring system (WPSS) was also divided into two groups: very low/low/Int and high/very high, and WPSS was able to predict the outcome of del(5q) patients more clearly than IPSS.Together with additional cytogenetic data, WPSS might be useful for clinical decision making in MDS patients with del(5q).

show abstract

Section: Discussionmentioning

confidence: 99%

Myelodysplastic syndrome with chromosome 5 abnormalities: a nationwide survey in Japan

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Monosomy 7 and del(7q) have been associated with an adverse outcome in AML, [3][4][5][6] suggesting that the critical region(s) in AML may be in the q-arm. [7][8][9][10] In this study, both EFS and OS were significantly worse for children with ALL with a loss involving chromosome 7 than for patients lacking this abnormality.…”

Section: Discussionmentioning

confidence: 99%

“…2 Monosomy 7 or deletion of 7q in these disorders is associated with poor prognosis. [3][4][5][6] It has been hypothesized that there is a tumor suppressor gene (TSG) on chromosome arm 7q that contributes to the pathogenesis of these diseases, and several chromosomal bands have been identified that contain commonly deleted segments, including 7q22 and different nonoverlapping regions in 7q31-q35. [7][8][9][10] However, a putative TSG has not yet been identified on 7q.…”

Section: Introductionmentioning

confidence: 99%

Deletion of 7p or monosomy 7 in pediatric acute lymphoblastic leukemia is an adverse prognostic factor: a report from the Children's Cancer Group

et al. 2004

View full text Add to dashboard Cite

Monosomy 7 or deletions of 7q are associated with many myeloid disorders; however, the significance of such abnormalities in childhood acute lymphoblastic leukemia (ALL) is unknown. Among 1880 children with ALL, 75 (4%) had losses involving chromosome 7, 16 (21%) with monosomy 7, 41 (55%) with losses of 7p (del(7p)), 16 (21%) with losses of 7q (del(7q)), and two (3%) with losses involving both arms. Patients with losses involving chromosome 7 were more likely to be X10 years old, National Cancer Institute (NCI) poor risk, and hypodiploid than patients lacking this abnormality. Patients with or without these abnormalities had similar early response to induction therapy. Event-free survival (EFS) and survival for patients with monosomy 7 (Po0.0001 and P ¼ 0.0007, respectively) or del(7p) (Po0.0001 and P ¼ 0.0001, respectively), but not of patients with del(7q), were significantly worse than those of patients lacking these abnormalities. The poorer EFS was maintained after adjustment for a Philadelphia (Ph) chromosome, NCI risk status, ploidy, or an abnormal 9p. However, the impact on survival was not maintained for monosomy 7 after adjustment for a Ph. These results indicate that the critical region of loss of chromosome 7 in pediatric ALL may be on the p-arm.

show abstract

“…The basic demographic, morphologic, cytogenetic and survival data on the present 372 AML and 389 MDS cases have been reported previously. [29][30][31] The diagnoses were based on the morphologic findings present at the time of karyotypic investigation. Survival was calculated from the time of diagnosis of t-MDS/t-AML until date of last follow-up (18 May 2001).…”

mentioning

confidence: 99%

Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001

et al. 2002

Self Cite

View full text Add to dashboard Cite

To ascertain the frequency of treatment-related acute myeloid leukemias and myelodysplastic syndromes (t-AML/t-MDS) in an unselected series, we have identified all adult cases analyzed in our department from 1976 to 1993. Further aims were to compare karyotypic features of t-AML/t-MDS with de novo AML/MDS, in our material as well as in 5098 unselected, cytogenetically abnormal, published cases, and to analyze associations between type of prior therapy and karyotype. Among our 372 AML and 389 MDS, 47 (13%) were t-AML and 62 (16%) were t-MDS. Clonal abnormalities were significantly more common in t-AML and t-MDS than in de novo disease (68% vs 50%, P Ͻ 0.05 and 84% vs 45%, P Ͻ 0.001, respectively). Among the available 4230 AML and 1629 MDS (the present series and published cases), 14% were t-AML and 15% were t-MDS. In t-AML/t-MDS, the number of anomalies and the ploidy levels differed significantly from de novo cases, with complex and hypodiploid karyotypes being more common in t-AML/t-MDS. In t-AML, unbalanced changes in general, t(1;3), der(1;7), 3p−, −5, 5q−, −7, 7q−, t(9;11), t(11;19), t(11q23), der(12p), −17, der(17p), −18, and −21 were significantly more frequent than in de novo AML. In t-MDS, −5, −7, 7q−, 13q−, der(17p), and −18 were significantly more common. Type of prior treatment correlated significantly with number of anomalies in t-AML and with ploidy levels in t-AML/t-MDS. The frequencies of several aberrations varied with type of therapy, eg, 5q− was more frequent in radiotherapyassociated t-MDS, monosomy 7 was more common in t-AML and t-MDS after treatment with alkylators, and t(11q23) in t-AML was associated with topoisomerase II inhibitors. Abnormalities significantly more common in de novo disease were +8 as a sole anomaly, balanced changes in general, t(8;21), t(9;22), t(15;17), inv(16), and t(21q22) in AML, and −Y, 5q−, and 20q− as sole anomalies and +8 in MDS. The results emphasize the strong association between previous genotoxic exposure and karyotypic features. Leukemia (2002) IntroductionEver since the mid-1970s, when the first case reports describing chromosomal abnormalities in treatment-related acute myeloid leukemias (t-AML) were published, 1,2 the cytogenetic features of t-AML and of therapy-associated myelodysplastic syndromes (t-MDS) have received much attention. 3,4 To date, two distinct karyotypic patterns that correlate with specific types of chemotherapeutic agents have emerged. Previous chemotherapy (CT) with alkylators (alk) has been strongly linked to the development of t-MDS/t-AML harboring unbal- anced changes, mainly whole or partial losses of chromosomes 5 and 7, often in complex, hypodiploid karyotypes, 5-9 whereas prior CT with DNA topoisomerase II inhibitors (topo II) has been associated with t-AML characterized by, in particular, translocations involving chromosome band 11q23 resulting in MLL gene rearrangements. 4,[10][11][12] It has been debated, but remains to be settled, whether prior radiotherapy (RT) alone or exposure to CT other than alk/topo II may correla...

show abstract

Survival time in a population-based consecutive series of adult acute myeloid leukemia – the prognostic impact of karyotype during the time period 1976–1993

Cited by 15 publications

References 36 publications

Myelodysplastic syndrome with chromosome 5 abnormalities: a nationwide survey in Japan

Myelodysplastic syndrome with chromosome 5 abnormalities: a nationwide survey in Japan

Deletion of 7p or monosomy 7 in pediatric acute lymphoblastic leukemia is an adverse prognostic factor: a report from the Children's Cancer Group

Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001

Contact Info

Product

Resources

About